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A B S T R A C T
Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people worldwide. Second-
generation antipsychotics (SGAs) are the cornerstone in the management of schizophrenia. However, despite
their efficacy in counteracting both positive and negative symptomatology of schizophrenia, recent clinical
observations have described an increase in the prevalence of metabolic disturbances in patients treated with
SGAs, including abnormal weight gain, hyperglycemia and dyslipidemia. While the molecular mechanisms re-
sponsible for these side-effects remain poorly understood, increasing evidence points to a link between SGAs and
adipose tissue depots of white, brown and beige adipocytes. In this review, we survey the present knowledge in
this area, with a particular focus on the molecular aspects of adipocyte biology including differentiation, lipid
metabolism, thermogenic function and the browning/beiging process.
1. Introduction
1.1. Etiology and pathophysiology of schizophrenia and its treatment with
antipsychotic agents
Schizophrenia is a chronic, severe mental disorder that affects about
21 million people worldwide. The disease typically manifests in late
adolescence/early adulthood and usually involves positive symptoms
that reflect an excess or distortion of normal functions, resulting in
behavior problems such as delusions, hallucinations, trouble thinking
and concentrating; and/or negative symptoms related to withdrawal or
lack of normal cognitive functions, including apathy, avolition, alogia
and anhedonia [1,2]. Often, the symptoms are associated with psy-
chotic episodes that disrupt the stability and quality of life of patients,
denying them a normal life in society. Fortunately, pharmacological
interventions are effective in suppressing the symptomatology
sufficiently, restoring a productive life and allowing the integration of
patients into society [3]. According to current guidelines, antipsychotic
agents are the first line of treatment in schizophrenia [4,5]. Because
discontinuation of treatment is associated with an exponential risk of
relapse as compared with maintenance therapy, patients generally
continue the same treatment that was effective in the acute phase for as
long as it is well tolerated.
Since the introduction of chlorpromazine in 1952, the first-genera-
tion antipsychotics (FGAs) have changed psychiatric care dramatically,
allowing many patients with debilitating and severe mental illnesses
(schizophrenia, bipolar mania and acute agitation, among other con-
ditions) to reintegrate into society. FGAs predominantly counteract the
positive symptoms of schizophrenia through mechanisms that remain
unknown. The most accepted hypothesis of FGAs action relates to the
dopaminergic theory of schizophrenia, which posits that the positive
symptomatology is caused by the increased subcortical release of
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dopamine and the subsequent enhanced activation of dopamine-2 (D2)
receptors [6,7], likely derived from disturbances in the cortical
pathway through the nucleus accumbens. Conversely, the negative
symptoms appear to be caused by blunted dopaminergic signaling
through reduced dopamine-1 receptor activity in the prefrontal cortex
and diminished nucleus caudatus activity [7–9]. Alterations in the ex-
pression and activity of dopamine-3 receptors have also been associated
with the negative symptoms of schizophrenia [10]. Some studies have
corroborated the dopaminergic theory of schizophrenia, showing that
D2 antagonists such as FGAs act on different dopaminergic pathways
(mesolimbic, mesocortical, nigrostriatal and tuberoinfundibular) to
control schizophrenia symptomatology. By contrast, D2 agonists in-
cluding l-3,4-dihydroxyphenylalanine (L-DOPA), cocaine and amphe-
tamines, trigger psychomimetic effects in individuals that are not
schizophrenic per se. Nevertheless, FGAs are associated with extra-
pyramidal side-effects such as dyskinesia and dystonia [11]. In an at-
tempt to counteract this, a variety of new agents were investigated in
the 1990s, leading to the approval of second-generation (atypical) an-
tipsychotics (SGAs), which are now the mainstay for patients with
schizophrenia and other psychotic disorders [4]. Beyond the interaction
of SGAs with dopaminergic receptors, as for FGAs, they also have the
ability to block serotonergic (5-HT2A and 5-HT2C) receptors, with a
higher affinity than that for D2 receptors [8,11], suggesting that al-
terations in serotoninergic pathways could also play a role in schizo-
phrenia development. More importantly, the neurological side-effects
associated with FGAs are not as evident in patients on SGAs, which can
counteract both positive and negative symptoms of the disease [4].
However, clinical observations have revealed a variety of discrete me-
tabolic dysfunctions in a relevant proportion of patients on SGAs, such
as abnormal body weight gain, hyperglycemia and dyslipidemia
[12–14]. These side-effects (Table 1) suggest that the use of SGAs has
indirect effects on different peripheral tissues and systems, including fat
depots, liver and immune cells.
1.2. Adipose tissue: a hub for energy balance and endocrine signaling
Abnormal body weight gain is a major side-effect of therapy with
SGAs [11] and is associated with an increase in fat (adipose) depots
[3,14,15]. Adipose tissue is a highly specialized organ regulating en-
ergy homeostasis and metabolism, and is comprised mainly of three
general classes of adipocytes in mammals – white, brown and beige
adipose cells – which have distinct developmental origins, morpholo-
gies, lipid droplet distribution, mitochondrial networks and gene ex-
pression patterns [16].
Functionally, white adipose tissue (WAT) is the predominant store
of surplus energy in the body, in the form of triglycerides (TGs), and
contains adipocytes with a large unilocular lipid droplet and few mi-
tochondria. WAT accounts for 5–50% of the total body weight in hu-
mans and includes both visceral (within the abdominal cavity) and
subcutaneous (underneath the skin) depots, with important ontogenetic
and metabolic differences between the two [16]. Under a state of po-
sitive energy balance, adipose tissue expands via hypertrophy of ex-
isting adipose cells and via hyperplasia, with de novo formation of
adipocytes. Beyond its classical role as an energy storage and release
unit, WAT also functions to protect other organs (liver and muscle)
from lipid-associated toxicity (lipotoxicity) [17] and is a key player in
endocrine signaling [18].
Brown adipose tissue (BAT) is much less abundant than WAT and is
located mainly in subcutaneous interscapular regions. BAT is char-
acterized by the presence of small multiocular adipocytes that were
initially perceived as skeletal muscle-like lineage cells, but more re-
cently their adipocyte origin has been suggested [19,20]. BAT is
abundant in mitochondria enriched in uncoupled protein-1 (UCP-1) in
the inner membrane, which functions to dissipate chemical energy in
the form of heat by uncoupling fuel oxidation from ATP synthesis
[21–23]. In humans, BAT was previously believed to exist only in
newborn infants, but it has recently been identified in adults in the
lower neck area [24–26], where its functions and characteristics are
currently under extensive study.
Beige adipocytes are mainly present in subcutaneous white depots
and in restricted amounts of visceral WAT [27]. Beige adipocytes are
considered brown-like thermogenic adipose cells with a similar multi-
locular lipid droplet morphology and UCP-1 expression, and are de-
veloped from the so-called beiging or browning of WAT. This differ-
entiation phenomenon is induced by cold stress or agonists that can
mimic this effect, such as β3-adrenergic agonists [28,29]. The origin of
beige adipocytes is, however, not completely understood and several
processes seem to be involved; for instance, they can be derived from a
beige progenitor lineage [19,27,30], but can also transdifferentiate
from mature white adipocytes [31,32], or even differentiate from other
origins [16].
As an endocrine organ, adipose tissue actively participates in in-
flammatory processes by producing and secreting a wide variety of
bioactive peptides including cytokines and the so-called adipokines
such as leptin and adiponectin. These peptides have both local and
distant actions related to the modulation of lipid and glucose metabo-
lism and energy balance [16].
Given the evident metabolic dysregulation in some patients on
SGAs, a better understanding of the effects of these drugs on adipocytes
will be important for elucidating the molecular mechanisms underlying
these dysfunctions in patients. Accordingly, this review will examine
recent advances in our understanding of the impact of SGAs on the
mechanisms of adipocyte differentiation and function.
2. Effect of second-generation antipsychotics on white adipose
tissue
WAT is organized into discrete depots – mainly visceral and
Table 1
List of first generation and second-generation antipsychotics mentioned in this review and their side-effect profiles.
Antipsychotics mentioned in this Review Extrapyramidal side effects in Humans Metabolic side effects in Humans
Sedation Cognitive impairment Tardive dyskinesia Diabetes Increased Lipids/dislipidemia Hyperprolactinemia
Chlorpromazine ++ ++ ++ +++ +++ +
Haloperidol + 0 ++ 0/+ 0/+ ++
Pimozide 0/+ + +++ 0/+ 0/+ ++
Clozapine +++ +++ 0 +++ ++ +
Olanzapine +/++ ++ 0/+ +++ +++ +
Aripiprazole 0/+ 0 0/+ 0/+ 0/+ 0
Quetiapine ++ +/++ 0/+ ++ ++ 0
Risperidone + 0 0/+ + + +++
Ziprasidone + 0 0/+ 0/+ 0/+ +
Blonanserin 0/+ 0 + 0/+ + +
0: none; 0/+ sporadic; +: occasionally; ++: recurrent; +++ very often.
V. Ferreira, et al. BBA - Molecular and Cell Biology of Lipids 1865 (2020) 158534
2
subcutaneous – that are differentially associated with insulin resistance
and the risk of metabolic syndrome. While the accumulation of visceral
WAT is considered deleterious, due to its promotion of inflammation,
subcutaneous WAT seems to be protective against the development of
metabolic diseases in mice and humans [33,34].
It has been described that patients with schizophrenia have sig-
nificantly more visceral WAT than healthy individuals [15], and this
could explain their susceptibility to develop insulin resistance and more
severe metabolic dysfunctions such as type 2 diabetes mellitus [35]. As
mentioned, SGAs therapy induces an increase of both subcutaneous and
visceral fat in some patients [15], and also alters the mechanisms of
differentiation and response to physiological stimulus, as described
below.
2.1. Effect of second-generation antipsychotics on the differentiation of
white adipocytes
A possible explanation for weight gain associated with SGAs is their
positive influence on the differentiation of preadipocytes to mature
adipocytes. In relation to adipocyte differentiation, the sterol regulatory
element-binding protein (SREBP) family of transcription factors, con-
stituted by the SREBP-1a and -1c isoforms (encoded by the SREBF1
gene) and SREBP-2 (encoded by SREBF2) [36], play a major regulatory
role. Yang et al. showed that treatment of differentiating murine 3T3-L1
preadipocytes with the SGA olanzapine (10 or 50 μM for 24 h) increases
TG accumulation and activates SREBP-1, accompanied by the over-
expression of fatty acid synthase (FAS), an enzymatic complex of long-
chain fatty acid synthesis [36]. They also found that SREBP-1, but not
the transcription factor CCAAT/enhancer binding protein α (C/EBP-α),
is overexpressed and activated in olanzapine-stimulated 3T3-L1 cells.
Similarly, olanzapine (100 μM for 3 h) increases lipogenesis and reduces
lipolysis [37]. Likewise, clozapine (10 μM) induces stearoyl-CoA desa-
turase-1 (SCD1) and SREBP-1 expression levels at both early (day 3)
and late (day 7) stages of human adipose-derived stem cells (ASC)
differentiation [38]. Overall, these studies show that some SGAs in-
crease the expression of SREBP-1 and its downstream lipogenic targets,
although to different levels. Indeed, it has been suggested that the ef-
fects of SGAs on lipid droplet formation (clozapine> olanzapine>
risperidone) depend on the nuclear translocation of SREBP-1 and the
subsequent modulation of adipogenesis [38]. Moreover, in the human
hepatic HepG2 cell line, treatment with olanzapine (10 and 50 μM for
24 h) increases SREBP-1 response element activity in a dose-dependent
manner [39]. However, these effects are not so evident in other hepatic
cell types treated with olanzapine, haloperidol or mirtazapine (25 μM
for 24 h), as reported by Raeder and co-workers [40]. Given the
aforementioned results in adipocyte culture, we speculate that in ad-
dition to acting on the central nervous system (CNS) leading to weight
gain and lipid abnormalities [41,42], SGAs function in a cell-autono-
mous manner by increasing lipogenesis.
The insulin-induced gene (Insig) family proteins are important ne-
gative regulators of SREBP function and lipogenesis. Insigs are SREBP-
chaperone proteins that form a complex with SREBP and SREBP clea-
vage-activating protein (SCAP) in the endoplasmic reticulum (ER).
When sterol levels are low, SREBPs are activated by proteolytic clea-
vage and the N-terminal domain is released from the ER and translo-
cates to the nucleus where it acts as a transcription factor for multiple
lipid biosynthesis genes [43]. The Insig family is composed of two
isoforms: Insig-1, a target of nuclear SREBPs whose mRNA levels are
directly associated with their presence in the nucleus, and Insig-2,
which is negatively regulated by insulin in a SREBP-independent
manner [36]. In sterol-replete conditions, Insig-2 can retain the SCAP/
SREBP complex in the ER [44]. Of interest, a relationship between
SREBP-induced lipid biosynthesis, Insig-2 blockade and SGA-associated
weight gain was described by Chen et al., showing that clozapine
(10 μM) significantly suppresses Insig-2 expression during adipogenesis
of human ASCs, at both early and induction (late) phases. Moreover,
after treatment, the levels of Insig-2 negatively correlated with the
expression of SREBP-1 and lipid-biosynthesis genes. Of note, the au-
thors found that on the third day of the differentiation, all of the SGAs
tested – clozapine (10 μM), olanzapine (1 μM) and risperidone (0.4 μM)
– decreased Insig-2 expression; however, only clozapine significantly
suppressed Insig-2 at day 7 of differentiation and, consequently, SREBP-
1 activity was increased [38]. Moreover, even though olanzapine
treatment did not maintain the suppression of Insig-2 expression on the
last day of differentiation, it increased SREBP-1 expression. Conversely,
Insig-2 overexpression during human ASC differentiation results in a
suppression of SREBP-1 expression, leading to the inhibition of SGA-
induced lipid biosynthesis [38]. This study implicates Insig-2 in the
pathogenesis of the metabolic dysfunctions developed by patients under
SGAs treatment. Despite the fact that the interactions between the two
Insig isoforms are related to SGA-induced metabolic syndrome, Insig-1
is reported not to correlate with these metabolic side effects per se [45]
(Fig. 1A).
In mammalian cells, peroxisome proliferator-activated receptor
gamma (PPAR-γ) is critical not only for adipogenic differentiation, but
also for the maintenance of the mature adipocyte phenotype [46,47]
and, together with C/EBPs, is considered a master regulator of adipo-
genesis [48]. Sertie et al. reported the impact of SGAs, particularly
clozapine (used at 20–30 μM) and olanzapine (40–100 μM), in the en-
hancement of both early (day 3) C/EBP-β and PPAR-γ expression, and
late (day 14) PPAR-γ and lipoprotein lipase (LPL) levels during adipo-
genic differentiation of human ASCs [49]. Consistent with this,
Hemmrich et al. differentiated human ASCs in the presence of clozapine
(5 and 50 μM) for the first 5 days and then in its absence for 9 additional
Fig. 1. Impact of SGAs in white adipocytes. A. Scheme of the molecular effects of SGAs in white adipocytes focusing on lipid-related proteins and enlargement of the
lipid droplets. B. List of the receptors through which SGAs can impact white adipocytes.
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days (14 days of differentiation in total), finding increased activity of
glycerol 3-phophatase dehydrogenase, another key marker of adipo-
genic differentiation. They also found that clozapine increases the
percentage of differentiated cells when compared with untreated con-
trols [50]. These results provide a plausible explanation as to why
clozapine treatment is associated with a higher risk of weight gain in
relation to other SGAs [51,52]. Likewise, other agents, particularly
pimozide (10 μM), is reported to promote adipogenesis of 3T3-L1 pre-
adipocytes up to day 6 of differentiation by inhibiting fatty acid binding
protein 4 and upregulating PPAR-γ protein levels of the cells [53]. Si-
milarly, treatment of human ASCs for 3 days with clozapine, olanza-
pine, quetiapine or risperidone (all used at 250 nM) increases total lipid
production, an effect blocked by the addition of a protein kinase C
(PKC)-β inhibitor [51]. At the molecular level, this study shows that
treatment of ASCs with SGAs, particularly clozapine, promotes the
translocation of PKC-β to the plasma membrane and its activation.
Importantly, adipogenesis of skeletal muscle-derived stem cells is also
boosted by SGAs, suggesting that the weight gain associated with SGAs
also involves the commitment of adipogenic features of other stem cell
pools [54].
The increase in body weight associated with SGAs treatment can
also result from alterations in adipocyte lipid storage (hypertrophy).
For instance, differentiation of rat ASCs in the presence of clozapine
(10 μM) increases the formation of lipid droplets, whereas the addition
of olanzapine (1 μM) or risperidone (0.4 μM) induces only a slight en-
hancement at day 7 [38]. Likewise, in adipocytes differentiated from
human mesenchymal stem cells (MSCs), olanzapine treatment
(5–100 μM) up to 12 days increases lipid accumulation in a dose-de-
pendent manner [52]. Further proteomic studies revealed that olanza-
pine upregulates the levels of perilipin-4 (PLIN4) and other enzymes
related to lipid metabolism including FAS. Indeed, MSCs differentiated
in the presence of olanzapine show enlarged lipid droplets coated with
PLIN1, 2 and 4. However, only PLIN2 protein levels are upregulated by
olanzapine at early stages of differentiation and decrease from day 12,
whereas PLIN4 and PLIN1 increase at later stages. While it is known
that PLIN proteins are regulated by PPAR-γ, the authors failed to find
alterations in its mRNA levels by olanzapine. However, C/EBP-α mRNA
was decreased at day 9–16 in the presence of olanzapine, which could
downregulate its target protein fatty acid translocase/CD36 in late
stages of differentiation [55]. Nonetheless, the relevance of this
downregulation is controversial as the deletion of fatty acid translo-
case/CD36 in mice was found to confer protection from high-fat diet-
induced adipose tissue deposition [56]. Of note, other genes encoding
relevant proteins of lipid metabolism such as SREBP-1c, FAS, LPL,
leptin and adiponectin, were unaltered by the treatment. The afore-
mentioned study also showed that the expression of adipose tissue tri-
glyceride lipase (ATGL) is increased by olanzapine. In adipocytes, ATGL
is localized on large PLIN1-positive lipid droplets and is liberated upon
PLIN1 phosphorylation, leading the authors to postulate that ATGL
expression increases in olanzapine-treated MSCs concomitant with the
accumulation of lipid droplets (Fig. 1, panel A). Moreover, changes in
gene expression and protein levels of PLIN family members by olan-
zapine might suggest a possible downstream mechanism for the in-
creased adiposity in patients undergoing treatment with this drug [55].
Dyslipidemia is another metabolic side-effect of SGAs therapy and is
directly related to the ability of adipocytes to sequester free fatty acids
(FFA). In this regard, a study with human adipocytes showed that
clozapine, olanzapine, quetiapine or risperidone (all tested at 50 or
100 μM) failed to inhibit fatty acid transport, concluding that this is
likely not the mechanism for dyslipidemia observed in patients treated
with SGAs [57]. Despite all these achievements, further studies are
required for a better understanding of the impact of SGAs on the early
and late events of adipogenesis, as well as on the hypertrophy of the
adipose cells.
2.2. Second-generation antipsychotics modify the endocrine function of
white adipocytes
Adipose tissue is a main player in systemic metabolism and in-
flammation, or so-called immunometabolism [16,58], and produces
and releases a plethora of biomolecules with paracrine, autocrine and
endocrine functions associated with the balance between energy ex-
penditure and intake, regulation of lipid and glucose homeostasis, and
also inflammatory processes [16].
Adiponectin is the most abundant of the adipokines and is also one
of the most relevant molecules secreted by mature adipocytes, and it is
negatively regulated in obesity, insulin resistance and metabolic syn-
drome [59]. Adiponectin modulates pathways related to carbohydrate
and lipid metabolism, and also vascular processes, due to its anti-in-
flammatory, anti-atherogenic and insulin sensitizing properties [60].
Several studies have investigated the adiponectin response to SGAs.
Human ASCs differentiated in the presence of clozapine (100 ng/ml),
quetiapine (50 ng/ml) or aripiprazole (100 ng/ml) show elevated adi-
ponectin expression [61] and, similarly, olanzapine (10 μM) treatment
induces early adiponectin expression in differentiating 3T3-L1 cells
[39]. In another study, short (2 days in mature adipocytes) or long
(10 days, including during differentiation) clozapine (10–30 μM) treat-
ment in 3T3-L1 adipocytes was found to decrease adiponectin secretion
without altering its mRNA levels [62], and 10 days exposure to blo-
nanserin (0.01–0.1 μM) also reduced adiponectin mRNA levels. Thus,
this opposite effect on adiponectin expression/secretion is intriguing
and may be dependent on the adipocyte origin or the sensitivity of the
cell-based systems to SGAs.
In contrast to adiponectin, leptin is a secreted adipokine that is
positively related to the amount of body fat, and modulates food intake
and energy expenditure [63]; accordingly, leptin is typically elevated in
the serum of obese patients [64]. Tsubai et al. reported that exposure of
3T3-L1 adipocytes to clozapine (10–30 μM) for 2 or 10 days decreases
leptin mRNA levels and also its secretion into the culture medium [62].
Of interest, this work tested the role of serotonergic 5-HT2c and hista-
minergic H1 receptors on the impact of clozapine in leptin expression
and secretion, as they are ubiquitously expressed in the brain and
peripheral tissues [65,66], and play a role in alterations/disorders of
eating patterns that lead to dysregulated lipid metabolism [67–69]. The
authors used histamine (H1 receptor agonist) and diphenhydramine (H1
receptor antagonist) as well as serotonin (5-HT2c receptor agonist) and
SB242084 (5-HT2c receptor antagonist). Short-term treatment of 3T3-
L1 cells with histamine or diphenhydramine failed to modify leptin
secretion, suggesting that this process is not mediated through H1 re-
ceptors. However, treatment with serotonin decreased leptin secretion
when compared to control-treated cells, but no synergistic or additive
effect was found when it was combined with clozapine (30 μM). In-
terestingly, SB242084 also decreased leptin secretion in 3T3-L1 cells
and further decreased secretion when combined with clozapine (30 and
50 μM) in a dose-dependent manner. Nevertheless, this relationship
seems to be more complex because serotonin failed to reverse this effect
by increasing leptin secretion (Fig. 1, panel B) [62]. By contrast, in the
study performed in human ASCs, treatment with SGAs increased leptin
expression [61]. Thus, more studies are required to fully understand the
mechanisms governing the interactions between SGAs and serotonergic
receptors in adipocyte hypertrophy and adipokine secretion.
Adipocytes secrete cytokines with pro-inflammatory properties,
which are the main drivers of the chronic low-grade inflammation as-
sociated with obesity-related metabolic abnormalities [70]. In the
aforementioned study of Sarvari et al. [58], in vitro treatment of human
ASCs with olanzapine, ziprasidone, clozapine, quetiapine, aripiprazole,
risperidone or haloperidol induced the expression of the transcription
factor nuclear factor-κB (NF-κB), a key component of the inflammatory
response, and this was accompanied by an increase in the expression of
the pro-inflammatory cytokines tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1β, IL-8 and MCP-1 and the release of IL-8 and MCP-1 into
V. Ferreira, et al. BBA - Molecular and Cell Biology of Lipids 1865 (2020) 158534
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the culture medium. These results suggest that antipsychotic treatments
might “prime” patients for developing a low-grade chronic pro-in-
flammatory state. Indeed, exposure of 3T3-L1 adipocytes to clozapine
(30 μM) for 10 days increases MCP-1 and IL-6 expression [62]. This
increase in the production of pro-inflammatory molecules in turn pro-
motes insulin resistance and exacerbates metabolic dysfunction
[71,72]. Of note, adiponectin can block local pro-inflammatory cyto-
kine production by antagonizing toll-like receptors (TLRs) [73] and
inhibiting NF-κB [74,75]. Thus, the hypoadiponectinemia associated
with hyperleptinemia following SGAs treatments is accompanied by the
increased expression and secretion of pro-inflammatory cytokines
[61,62]. The altered pattern of pro-inflammatory cytokine secretion in
adipocytes and the “shotgun” affinity of SGAs for several receptors in-
cluding histaminergic H1, serotonergic 5-HT2c, and adrenergic re-
ceptors [35], is likely the cause of the development of insulin resistance
and type 2 diabetes mellitus associated to the treatment with theses
drugs.
2.3. Second-generation antipsychotics modulate insulin sensitivity and
glucose uptake in white adipocytes
In addition to the control of whole body energetic balance, adipose
tissue also regulates glucose and lipid metabolism [16,58,76]. Glucose
transport resulting from activation of insulin signaling is highly re-
levant because it provides both fatty acids and glycerol for TG synthesis
[77,78]. Vestri et al. compared the effects of clozapine, olanzapine,
risperidone and quetiapine (1–500 μM) with the FGAs butyrophenone
and trifluoperazine for insulin-induced glucose transport and lipogen-
esis/lipolysis in 3T3-L1 cells and rat primary adipocytes. In both sys-
tems, olanzapine and clozapine at concentrations as low as 5 μM
strongly reduced insulin-induced glucose transport, whereas the FGAs
failed to modify this response. Moreover, all of the antipsychotics
(tested at 100 μM) increased basal and insulin-induced glucose oxida-
tion rates [37]. Interestingly, another study showed that 3T3-L1 cells
treated with haloperidol, quetiapine or clozapine at 10 μM, but not
1 μM, present reduced glucose uptake without alterations in insulin
sensitivity or in Akt/protein kinase B activation [79]. In the same line,
Robinson et al. found that therapeutic concentrations of olanzapine
(7–350 nM, see Table 2) failed to alter basal and insulin-induced glu-
cose transport in 3T3-L1 cells [80]. These results suggest that the effects
of SGAs on glucose transport are dose-dependent. Moreover, FGAs did
not affect lipolysis in response to isoproterenol or glucose uptake in
response to insulin, which might explain why conventional therapies
are less associated with secondary metabolic side effects [37].
2.4. White adipose tissue and antipsychotic effects in animal models:
dysregulation of lipid metabolism
Animal models provide a translational platform to decipher the
molecular basis of the metabolic side effects associated with SGAs.
Several studies have reported that clozapine and olanzapine are re-
sponsible for the higher weight gain associated with deficits in glucose
and lipid metabolism in rodents [81–84]. For example, Yang et al.
described that female Sprague-Dawley rats treated with olanzapine
(2mg/kg twice a day by oral gavage) for 2 weeks show increases in
total body weight gain, which is mainly due to an increase in liver and
WAT weight [85]. Moreover, the animals develop hyperlipidemia, hy-
perglycemia, hyperinsulinemia, insulin resistance and present elevated
serum IL-6 levels together with tissue chromium depletion. Interest-
ingly, daily supplementation of chromium during olanzapine treatment
produces a milder phenotype and supplementation with AICAR, an 5′
adenosine monophosphate-activated protein kinase (AMPK) activator,
ameliorates olanzapine-induced hyperglycemia and hyperlipidemia,
suggesting that low chromium and AMPK activity are related to olan-
zapine-induced metabolic dysfunction [85]. Interestingly, female rats
are reported to be more susceptible than male rats to the metabolic
damaging effects of SGAs [81,86]. Albaugh et al. reported that an in-
creasing dosing regimen of olanzapine mixed in cookie dough (4mg/kg
from day 0–6; 8mg/kg from day 7–20 and 12mg/kg from day 21–29)
increases the body weight of female, but not male, Wistar and Sprague-
Dawley rats [81]. Comparable results were previously reported by
Pouzet and co-workers in female Wistar rats treated with 5 and 20mg/
kg of olanzapine via oral administration for 21 days [86]. Furthermore,
Goudie et al. showed that female Wistar rats injected intraperitoneally
with olanzapine (4mg/kg) for 19 days increased their body weight
[83]. Of note, it has been described that the weight gain is very fast at
the beginning of the treatment and is reversible once treatment is ended
[83,86]. In this respect, Albaugh et al. provided evidence for the as-
sociation between body weight gain and hyperphagia in female rats
receiving olanzapine self-administered via cookie dough, starting from
the first 24 h of treatment [81]. In the same study, olanzapine con-
sumption led to an increase in leptin levels and adiposity, and induced
mild insulin resistance from day 12 of treatment, suggesting that
olanzapine-induced weight gain could be a secondary effect of hyper-
phagia related to leptin resistance (hyperleptinemia). By contrast, in a
study performed in female Sprague-Dawley rats injected in-
tramuscularly with olanzapine (100mg/kg) for 14 days in a 4-injection
treatment, Horska et al. reported body weight gain together with a
significant increase in the amount of visceral white fat, but without
hyperphagia [87]. Furthermore, in addition to increases in both adip-
osity and adipocyte size, Tan et al. reported that olanzapine treatment
(ranging from 0.003mg/ml to 0.03mg/ml) in the drinking water
causes morphological alterations in subcutaneous WAT of female
Wistar rats, an effect related to an increase in the number of un-
differentiated adipose cells in this depot that was detected as early as
the third day of treatment in a dose- and time-dependent manner, but
independently of the body weight gain [87,88].
In contrast to what is found in female animals treated with SGAs,
the body weight increase is more difficult to mimic in males. Minet-
Ringuet et al. showed that male Sprague-Dawley rats fed with an SGAs-
supplemented diet for 5 weeks (1mg/kg haloperidol or olanzapine and
10mg/kg ziprasidone) did not gain body weight but did show increased
adiposity in subcutaneous and visceral adipose depots [86]. A deeper
analysis of adipocytes isolated from these treated animals showed no
alterations in basal lipolytic activity; however, olanzapine reduced the
lipolytic effects triggered by the β-adrenergic agonist isoprenaline or
the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX).
Moreover, the anti-lipolytic actions of insulin, the adenosine analogue
phenylisopropyladenosine, or the α2-adrenergic agonist UK14304,
were unaltered in olanzapine-treated primary adipocytes. Overall, the
results of this study point to a reduction of β-adrenergic receptor sen-
sitivity by olanzapine, which might explain its negative impact on lipid
metabolism. However, the fact that IBMX-induced lipolysis was also
impaired suggests that the molecular mechanisms might be more
complex than the blockade of β-adrenergic receptors by SGAs [89]. On
the other hand, olanzapine, haloperidol and ziprasidone are moderate
α1 and α2-adrenergic receptor antagonists [90], but since α1-adre-
nergic receptors are not involved in lipolysis in rats [91], it is unlikely
that they are implicated in the mechanism of action of these drugs.
Table 2
Therapeutic reference ranges of different SGAs in accordance with the steady-
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Moreover, in the study by Minet-Ringuet et al., the fact that SGAs
treatment failed to counteract the inhibition of lipolysis induced by α2-
adrenergic receptor agonists [89] discounts these receptors in the me-
chanism by which SGAs disrupt lipid mobilization.
Lipid homeostasis is the balance between lipogenesis and lipolysis.
Interestingly, male Sprague-Dawley animals treated with olanzapine
present an increased expression of FAS and a decreased expression of
hormone-sensitive lipase (HSL) in adipocytes, thus favoring lipid
synthesis over lipolysis, and providing a possible explanation for the
increase in adipose depots in rats [89]. By contrast, Victoriano et al.
reported that male Sprague-Dawley rats treated with olanzapine (2mg/
kg) or haloperidol (1 mg/kg) mixed in the food for 46 days showed no
changes in the levels of lipogenic markers (FAS, and acetyl-CoA car-
boxylase (ACC)) and lipolytic enzymes (LPL and HSL) in WAT [92].
Clearly, more preclinical studies are needed to fully understand the
molecular basis of the impact of SGAs in lipid metabolism, including
gender intrinsic susceptibility, to be translated to humans.
2.4.1. Effect of second-generation antipsychotics on hormone/cytokine
expression and secretion in WAT
As stated earlier, adipose tissue is now recognized as a main player
in the development of systemic inflammation and, consequently, of
insulin resistance and metabolic dysfunction [93,94]. While the me-
chanisms through which SGAs influence systemic and/or local in-
flammation remain unclear, it has been hypothesized that adipose
tissue is responsible for the inflammatory response induced by SGAs,
which in turn is the main cause of the metabolic dysfunctions associated
with antipsychotic therapies [93]. By treating female Balb/c mice and
Sprague-Dawley rats intraperitoneally with olanzapine (10mg/kg) for
8 weeks, Li and co-workers found an increase in the levels of circulating
pro-inflammatory cytokines TNF-α, IL-6, IL-8 and IL-1β, which corre-
lated with their elevated mRNA expression in WAT [95]. Similarly,
administration of olanzapine (10mg/kg) via osmotic mini-pumps in
male Sprague-Dawley rats increases the levels of IL-6 and F4/80 im-
munostaining in WAT samples, which positively correlated with the
levels of translocator protein (TSPO) – a target for radiotracers puta-
tively indicating microgliosis in clinical neuroimaging studies –
whereas no changes were found in the abundance of IL-1β, IL-4, IL-5,
IFN-γ or TNF-α [93]. Using oral administration of olanzapine (1mg/kg
olanzapine, 3 times daily) in female Sprague-Dawley rats, Zhang et al.
reported an enhancement in monocyte infiltration in WAT in parallel
with body weight gain and an increase in adipocytes size [96]. More-
over, the authors found a high correlation between adipocytes size and
macrophage infiltration in WAT, and this was accompanied by an up-
regulation of TNF-α, IL-1β and IL-6. Interestingly, the inflammatory
response in the WAT of SGAs-treated animals also might have a gender-
dependent component. For example, Davey et al. tested the effects of
olanzapine (2 or 4mg/kg) administered intraperitoneally twice daily in
male and female Sprague-Dawley rats, finding that female rats gained
more body weight than males, an effect associated with hyperphagia
[97]. Also, female, but not male, animals showed an up-regulation of IL-
6 in WAT and elevated plasma levels of IL-8 and IL-1β. However,
adiposity and macrophage infiltration was increased by olanzapine
treatment in both genders, together with alterations in the gut micro-
biota [97]. The aforementioned study of Victoriano et al. performed in
male Sprague-Dawley rats treated with olanzapine or haloperidol mixed
in the food also described WAT inflammation that manifested as ele-
vated TNF-α mRNA levels and infiltration of CD68-positive cells [92].
Since SGAs treatment leads to NF-κB overexpression in human ASCs
[61], and the relationship between inflammation and insulin resistance
is well documented [98], a shift to a more pro-inflammatory profile
might explain some of the metabolic dysfunctions described in adipose
tissue after SGAs treatment. Accordingly, NF-κB could be a potential
target to prevent and/or mitigate olanzapine-induced insulin resistance
due to WAT inflammation [95].
It is important to mention that the action of SGAs in the CNS might
also play a relevant role in appetite and food intake patterns, since
olanzapine might activate the melanin-concentrating hormone system
(feeding-initiation system) in the lateral hypothalamus that has pro-
jections into the nucleus accumbens [42] enhancing food intake. Re-
garding the CNS-mediated effects of SGAs that result in a pro-in-
flammatory profile, Guesdon et al. described an effect of olanzapine
(1mg/kg) administration in male Wistar rats for 13 days via implanted
mini-pumps by moderately increasing the mRNA levels of melanin-
concentrating hormone receptor in the nucleus accumbens shell [41].
Over time, this could lead to increased food intake and, consequently,
in adipose tissue deposition that can per se recruit immune cells to the
fat depots, thereby triggering inflammatory processes. However, as
mentioned above, the link between peripheral and central effects fol-
lowing SGAs treatment remains poorly understood and needs to be
investigated in future studies.
2.4.2. In vivo insulin-related disturbances in WAT by second-generation
antipsychotics
Several animal studies have reported a direct influence of SGAs in
the response of WAT to insulin. In this line, Cui et al. reported that the
increased body weight in female C57Bl/6 female mice treated with
olanzapine (3mg/kg/day) mixed in the food for 2, 4 or 8 weeks as-
sociates with hyperinsulinemia and insulin resistance [99]. These
findings were corroborated by Coccurello et al. in the same animal
model [100], and also by Hou et al. in female C57Bl/6 mice receiving
olanzapine (6mg/kg) via oral gavage for 7 weeks [101]. Calevro et al.
hypothesize that the insulin resistance in treated animals is closely re-
lated to inflammation since olanzapine increases macrophage infiltra-
tion and pro-inflammatory cytokine expression in WAT, particularly IL-
6 [93]. Also, the effect of SGAs on the Wnt signaling pathway seems to
be relevant for the alterations of glucose metabolism and insulin sen-
sitivity in adipose tissue. In this regard, Li and coworkers found that, in
addition to an increase in insulin levels during fasting, the expression of
TFC7L2, a key effector of the Wnt pathway, was increased in the WAT,
liver and skeletal muscle of male C57Bl/6 male treated with olanzapine
(4mg/kg/day) via oral gavage for 8 weeks. The addition of metformin,
an anti-hyperglycemic drug, effectively blocked the changes in insulin
plasma levels and TFC7L2 expression, suggesting a potential correlation
between olanzapine-induced insulin dysfunctions and TCF7L2 [102].
Also, at the molecular level, the final stage of the insulin-signaling
cascade in adipose tissue is the translocation of glucose transporter-4
(GLUT4) to the plasma membrane. However, hyperinsulinemic-eu-
glycemic clamp studies performed in male Sprague-Dawley rats treated
with olanzapine mixed in cookie dough with an increasing dose re-
gimen (day 0–6: 4mg/kg/day; day 7–13: 8mg/kg/day and day 14–29:
12mg/kg/day) failed to find alterations in adipose tissue glucose up-
take although glucose uptake was impaired in skeletal muscle [103].
Besides the general direct relationship of insulin resistance and
SGAs, a study in obese male C57Bl/6 mice found that olanzapine
treatment (2 mg/kg/day) via oral gavage, once daily for 4 weeks, in-
creased insulin sensitivity by lowering glucose and insulin plasma le-
vels, an effect related to autophagy by potentiation of lysosomal func-
tion in adipocytes [104]. Thus, further research will provide new
insights to fully understand the effect of these therapies in vivo in order
to unravel their clinical relevance.
2.5. Direct and indirect effects of second-generation antipsychotics in
human WAT
Human studies are indispensable to translate data on the mechan-
isms of action of SGAs identified in cellular or animal models, since the
latter do not fully recapitulate the disease in patients. Regarding the
effect of SGAs in adipokine expression and insulin resistance, the levels
of the pro-inflammatory adipokine resistin are known to be elevated in
patients with schizophrenia under stable therapy with clozapine
[105,106], and correlate with circulating IL-1Ra, TNF-α and C-reactive
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protein [107]. In line with these results, Sapra and co-workers com-
pared body weight and several inflammatory indicators between a
group of 8 non-diabetic men with schizophrenia under treatment for at
least 6 months with SGAs (independently of the chosen agent) and age-
and body mass-index (BMI)-matched healthy men, finding that adipo-
nectin plasma levels were lower and C-reactive protein levels were
higher in the former after an overnight fast, which associated with in-
creased insulin resistance [108]. Likewise, in an open-label prospective
single-center study with 113 patients treated either with risperidone
(54 patients with an average dosage of 4.4mg/day) or olanzapine (59
patients with an average dose of 17.4 mg/day), body weight gain and
the prevalence of metabolic syndrome were significantly greater in the
olanzapine group than in the risperidone group. Also, whereas adipo-
nectin levels significantly increased in the risperidone group over time,
they significantly decreased in olanzapine-treated patients. By contrast,
no significant differences were found between the groups for fasting
glucose, insulin levels and insulin resistance, suggesting that the effect
of olanzapine on adiponectin levels precedes dysfunctions in whole-
body glucose metabolism [109]. In a similar type of study, Richards
et al. [110] examined the effects of olanzapine and other SGAs on the
levels of adiponectin in patients with schizophrenia versus matched
healthy controls, finding olanzapine-associated hypoadiponectinemia
with a specific decrease of the high molecular weight forms of the
protein. However, the study failed to find alterations in adiponectin
expression or in multimer composition in primary adipocytes isolated
from subcutaneous WAT and treated ex vivo with olanzapine (10 ng/ml)
for up to 7 days. These results point to the notion that alterations in
adiponectin expression and secretion might occur progressively.
Beyond the specific effects of SGAs on metabolic parameters, dis-
ease-specific changes should also be considered. In a study performed
with 9 medication-free non-diabetic patients and matched controls,
Cohn et al. provided evidence for schizophrenia-related insulin re-
sistance with an inadequate compensation in insulin secretion [111].
However, this was not associated with a significant loss of adiponectin
levels, as reported in another study of medication-free patients with
schizophrenia [112]. It is known that adiponectin levels can be influ-
enced by gender, as testosterone modulates adiponectin expression and
the secretion of multimers in vitro [113]. Therefore, indirect and direct
drug effects, inflammatory phenomena and/or hypoadiponectinemia
can also be considered as potential mechanisms for the metabolic dis-
turbances induced by SGAs [108]. Likewise, plasma levels of calcium
binding-protein B (S100B) are increased in female, but not male, pa-
tients treated with clozapine (125–900mg/day) and positively corre-
late with BMI, pointing to a possible link between this protein and in-
creased adiposity [114]. It should be mentioned that despite the belief
for astrocytes as the only cells that express and secrete S100B, adipo-
cytes have also been shown to secrete S100B in a process that is ne-
gatively controlled by insulin [115]. S100B inhibits adenylate cyclase
by activating D2 receptors and enhancing the extracellular signal-
regulated kinases (ERK) in astrocytes [116] and, accordingly, the
S100B/D2-receptor complex is a potential molecular target of the SGAs
[114].
Healthy volunteers are used in clinical trial studies because they are
normally naive to the tested pharmacological treatments and can pro-
vide information on the of the treatment per se, independently of pa-
thology. In healthy volunteers, a single dose of olanzapine (10mg)
elevates fasting glucose levels in the first 4.25 h after administration,
without altering body weight, and also decreases serum cortisol and
FFA levels [117]. Since cortisol activates hepatic-sensitive LPL and
ATGL in adipocytes [118], its decrease could explain the reduction in
FFA levels. A decrease in fasting and postprandial FFA concentrations
was also found in healthy volunteers that received olanzapine (10mg/
day) over 8 days, which was associated with increased nocturnal adi-
ponectin levels independently of BMI alterations [119]. Moreover,
15 days treatment of olanzapine (10mg/day) in healthy men elevates
the levels of adiponectin, leptin and TNF-α, and decreases those of
ghrelin, with no correlation to changes in adiposity [120]. Overall,
these studies illustrate the direct effect of SGAs on the organism in-
dependently of alterations in body weight or adiposity [117].
Because schizophrenia can manifest in early adulthood, some stu-
dies have focused on younger cohorts of patients. A study on SGAs-
naive 6–18-year-old patients diagnosed with disruptive behavior dis-
orders and treated randomly with aripiprazole, olanzapine or risper-
idone (commonly used in children) for 12 weeks showed that olanza-
pine leads to a higher weight gain (4.12%) when compared with
aripiprazole (1.66%) or risperidone (1.18%), in association with an
increase in subcutaneous fat [119]. Also, patients treated with olanza-
pine or aripiprazole show a reduction in insulin-stimulated glucose
uptake (29.34% and 30.26%, respectively), indicating insulin re-
sistance. The increase in body weight and reduced insulin sensitivity in
the first 12 weeks of treatment might be responsible for the future
cardiometabolic morbidity and mortality associated with SGAs therapy
in the young population [121].
The recent introduction of co-therapies has ameliorated some of the
SGAs-induced metabolic side-effects. For instance, in a cohort of 30
patients with schizophrenia under stable treatment with olanzapine,
Taveira and co-workers tested the effect of co-administration of na-
proxen, an opioid receptor antagonist. This combinatorial therapy de-
creased body fat mass and increased free-fat mass, conferring protection
against weight gain. This study does not prove that olanzapine-asso-
ciated weight gain is induced by activation of the opioid system since
by itself this system has the ability to improve body weight control, but
suggests that blockade of opioid receptors could counteract the dysre-
gulation of lipid metabolism associated with SGAs treatment [122].
The molecular impact of SGAs therapy for human adipose tissue is
still poorly understood and many contradictory reports have appeared
in the literature. A possible reason for these discrepancies is the mis-
match of the control groups used in clinical studies (age, BMI, sex and
smoking status, among other parameters). Moreover, the effect of SGAs
is clearly different between healthy volunteers and patients with schi-
zophrenia or other psychotic disturbances, and so it is possible that
disease-specific alterations are overlooked when using healthy subjects.
Of interest, alterations in adiposity and increased BMI observed in in-
dividuals undergoing SGAs treatments are closely related to cardio-
metabolic comorbidity and mortality. Accordingly, further studies are
required to understand the direct (or indirect) impact of these agents in
human adipose tissue with regard to differentiation, gene expression,
metabolic routes and secretory patterns.
3. Effect of second generation antipsychotics in brown adipose
tissue
BAT is the main player in adaptive thermogenesis, which functions
to maintain the core body temperature in cold environments. In con-
trast to WAT, BAT is defined by the expression of the UCP-1, which
burns metabolic substrates and dissipates energy in the form of heat
[21–23]. Despite their different functions, however, the differentiation
of white and brown adipocytes is controlled by similar transcription
cascades [123], although brown adipogenesis requires the expression of
additional transcription factors such as the zinc protein PRDM16, which
forms a complex with C/EBP-β and activates PPAR-γ2, resulting in the
expression of BAT-specific markers such as UCP-1, peroxisome pro-
liferator-activated receptor gamma coactivator 1 alpha (PGC-1α) and
Cidea [124].
3.1. The impact of second-generation antipsychotics on BAT thermogenesis
BAT was recognized for many years to be functionally important for
cold acclimatization in small mammals, such as mice and rats, and in
newborn humans. Recent studies using 18F-fluorodeoxyglucose positron
emission tomography combined with computed tomography have
proved the existence of discrete areas of metabolically-active BAT in
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adult humans [24,125], which is functionally controlled by both ca-
techolamines and insulin [126]. Whereas healthy brown adipocyte
differentiation increases energy expenditure and contributes to the re-
duction of weight gain [127], diminished brown adipogenesis is related
to obesity and insulin resistance [128].
In an attempt to unravel the involvement of brown adipocytes in
SGAs-induced weight gain, Oh et al. differentiated a murine brown
adipocyte cell line in the presence of clozapine (40 μM), quetiapine
(30 μM) or ziprasidone (10 μM). At day 8 of differentiation, clozapine
inhibited almost completely the expression of PRDM16, UCP-1 and
Cidea. Quetiapine also reduced the expression of these genes, but its
effect was less robust. Moreover, ziprasidone treatment inhibited PPAR-
γ expression at the initiation, but not at the end, of the differentiation
process. These findings correlated with the Oil Red-O staining of lipids,
which showed an almost complete inhibition of brown adipogenesis by
clozapine, moderate inhibition by quetiapine, and no inhibition by zi-
prasidone [129]. In parallel to the thermogenic program, it is well
known in rodents that brown adipocytes differentiate at the end of fetal
life via an adipogenic program related to lipid synthesis and the ex-
pression of lipogenic enzymes, resulting in a multilocular fat droplets
phenotype [130]. In the aforementioned study, clozapine reduced the
expression levels of genes encoding ACC, SCD1, GLUT4, adipocyte
protein 2 (AP2) and CD36, but not FAS. In contrast to the response of
clozapine, quetiapine increased ACC and FAS levels, whereas ziprasi-
done treatment did not modulate lipogenic gene expression [129]
(Fig. 2, panel A). Of interest, the effects of SGAs in brown adipocytes
differentiation correlate with their ability to induce weight gain in
patients (clozapine> quetiapine> ziprasidone). Overall, these results
support the hypothesis that inhibition of brown adipogenesis may be a
mechanism by which SGAs induce weight gain as a side-effect [129].
Contrasting with these findings, Ota et al. reported that male Sprague-
Dawley rats treated subcutaneously with risperidone (0.1 mg/kg/day)
for 21 days present hypothermia without changes in adipogenic, lipo-
genenic or thermogenic gene expression programs in BAT [131].
As mentioned above, hyperphagia is believed to be the main cause
of weight gain induced by short-term SGAs treatments. However, in
long-term treatment, when food intake is normalized, a reduction in
energy expenditure due to diminished thermogenesis and locomotor
activity is likely responsible for body weight increase. Zhang and co-
workers found in female Sprague-Dawley rats that a 34-day treatment
with olanzapine (1mg/kg, 3 times daily) mixed in cookie dough sig-
nificantly reduces BAT temperature detected at 45–150min post-
treatment. This decrease was associated with reductions in UCP-1 and
PGC-1α levels and a diminished abundance of brown adipocytes,
suggesting that olanzapine induces both BAT morphological alterations
and deficiency in its thermogenic function [132]. In addition to these
studies, it should be noted that a direct link between hyperphagia and
BAT thermogenesis has been recently identified. After a meal, an in-
crease in the gut hormone secretin in circulation activates BAT ther-
mogenesis by binding to its receptor in brown adipocytes thereby sti-
mulating lipolysis, which is sensed in the brain and promotes satiation
[133]. Whether this regulatory mechanism is affected by SGA treat-
ments remains to be elucidated.
The demonstration of active BAT metabolism in adult humans
[24–26,125,134] has led to the hypothesis that heat production in BAT
could contribute to emotional hyperthermia. Indeed, mild psycholo-
gical stress has recently been shown to activate BAT thermogenesis in
adult humans [135]. Related to this, Blessing et al. conducted a study in
male Sprague-Dawley rats treated subcutaneously or intraperitoneally
(catheter) with the FGA chlorpromazine (0.1–5mg/kg) or with the SGA
clozapine (30 μg–2mg/kg) or risperidone (6.25 μg–1mg/kg) and ex-
posed to an intruder rat. The objective of the study was to understand
the effect of the antipsychotic agents on emotional hyperthermia, which
activates BAT thermogenesis and tail artery constriction. All of the
antipsychotics tested strongly reduced the intruder-elicited BAT ther-
mogenesis and artery tail vasocontriction, diminishing the emotional
hyperthermia in a dose-dependent manner [136]. Moreover, all of the
doses required to elicit an effect on the thermogenic capacity of BAT
were lower than those that impact cardiovascular parameters induced
by open field stress [137], acoustic startle response [138] or pre-pulse
inhibition [139–141], indicating a higher sensitivity of BAT to these
drugs. Even though the D2 antagonist chlorpromazine could inhibit the
thermoregulatory actions in a manner similar to clozapine or risper-
idone, this does not necessarily mean that the mechanism of action is
dependent on D2 receptor blockade, as a previous study with the FGA
haloperidol, another potent D2 antagonist, failed to show an acute ef-
fect on resting body temperature when administered subcutaneously to
male Sprague-Dawley rats in one single dose (up to 3mg/kg) [142].
Blessing et al. also tested the selective and potent D2 antagonist ra-
clopride, finding that it did not reduce intruder-elicited BAT thermo-
genesis [136]. By contrast, the hypothermic action of the D2 agonist
apomorphine was counteracted by haloperidol in a dose-dependent
manner [142]. Similarly, a low dose of the D2 antagonist spiperone
ablated apomorphine-induced hypothermia as well as quinpirole (D2
agonist)-mediated inhibition of BAT thermogenesis. Moreover, spi-
perone diminished the tail artery vasoconstriction induced by clozapine
[143]. All of these findings suggest that perhaps the stimulation, and
not the blockade, of dopamine D2 receptors in the CNS reduces body
Fig. 2. Impact of SGAs in brown adipogenesis and
BAT thermogenic function. A. Scheme of the mole-
cular cell autonomous effects of SGAs in brown adi-
pocytes, focusing on their effects in lipid-related and
thermogenic proteins, as well as the inhibition of
brown adipogenesis. B. List of the receptors in the
CNS through which SGAs.
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temperature [136,143]. Additionally, pharmacological studies demon-
strated that 5-HT1A agonists and 5-HT2A antagonists reduce BAT ther-
mogenesis and cutaneous vasoconstriction thereby both contributing to
hypothermia [144,145], and also agonists of α2-adrenergic signaling
reduce BAT thermogenesis [146]. Conversely, activation of H1 re-
ceptors in histamine-producing neurons increases body temperature in
association with stimulation of the ascending arousal system [147]. Due
to their shotgun binding profile, clozapine and risperidone impact all of
the aforementioned families of receptors, motivating the hypothesis
that perhaps the influence of these SGAs on BAT thermogenic function
is a consequence of synergistic interactions among them [136] (Fig. 2,
panel B). These observations are still preliminary and further in-
vestigation is needed to understand how antipsychotics impact on BAT
thermogenesis.
BAT activation may be critical for the gender differences found in
weight gain upon SGAs treatment. This hypothesis was tested by Ferno
et al. in male Sprague-Dawley rats treated with two intramuscular in-
jections of commercially available olanzapine, pamoate depot for-
mulation (ZypAdheras®, 100mg/kg) at days 0 and 9, and sacrificed at
day 17 after the first injection [148]. The dose was previously used by
the authors to induce hyperphagia in female Sprague-Dawley rats
[149]. A second group of animals fed a high-fat diet was also treated.
The authors found that olanzapine transiently increases food intake in
the days following its administration, with a prolonged effect in the
group fed a standard diet. However, despite the induction of temporary
hyperphagia, the olanzapine-treated groups (independently of diet)
presented a decrease in body weight, suggesting reduced feed effi-
ciency. Yet, the treatment failed to modify the mRNA levels of UCP-1
and PGC-1α in the BAT of the experimental groups, likely excluding an
effect mediated by increased BAT activity. The authors also treated
another cohort of animals with a single higher dose of the same for-
mulation of olanzapine (150, 200 or 250mg/kg) and sacrificed them at
day 13 post-injection. This acute treatment also led to a transient in-
crease in food intake accompanied by a decrease in cumulative weight
gain which, contrary to the previous treatment, could be explained by
an up-regulation of UCP-1 and PGC-1α in the BAT of olanzapine-treated
animals indicating increased energy expenditure [148]. This is contrary
to what has been reported in female animals [149,150]. For example,
Skrede et al. described that treatment of female Sprague-Dawley rats
with olanzapine (6mg/kg) twice daily by oral gavage for 13 days de-
creases both UCP-1 and PGC-1α in BAT and increases weight gain. Of
note, when the animals were treated with aripiprazole in the same
experimental set-up, only PGC-1α expression decreased [151]. In an-
other study [150], female Sprague-Dawley rats treated orally with
olanzapine (6mg/kg/day) for 24 days displayed a transient increase in
food intake together with increased body weight gain along the treat-
ment, as compared with non-treated controls. Likewise, in pair-fed rats
receiving olanzapine, body weight increased along the treatment as
compared with vehicle-treated rats, in association with decreased en-
ergy expenditure, a reduction in BAT temperature and a decreased
expression of UCP-1 protein. Interestingly, an increase in FOS protein
was found in spinal cord neurons projecting to discrete sites in the
brainstem and hypothalamus, suggesting their excitatory activation,
and some of these neurons, specifically those located at the perifornical
region of the lateral hypothalamus, were positive for orexin A [150], a
key neuropeptide in BAT-directed neurons in the lateral hypothalamus
[152]. In a previous study, the activation of these neurons upon olan-
zapine treatment was associated with hyperphagia, likely due to their
projections to the areas associated with hunger in the cerebral cortex
[153]. Additionally, the same perifornical orexin A-positive neurons in
the anterior cingulated cortex project axon collaterals to sites that are
related to food intake and thermogenesis [154], corroborating that the
activation of these neurons by olanzapine provides a possible ex-
planation for SGA-mediated changes in both feeding and energy ex-
penditure, thereby leading to weight gain. Another possible factor re-
lated to the decrease in thermogenesis by SGAs is the stimulation of
different sub-regions of the lateral hypothalamus that induce inhibitory
responses, constraining sympathetic nerve activity [155], although it
has yet to be tested in BAT. In this scenario, the response to olanzapine
would mediate inhibitory actions at the spinal-cord level, but more
work is needed to fully understand the involvement of hypothalamus-
BAT axis in the side effects induced by SGAs [150]. Moreover, S100B
and its chaperone calsyntenin 3β have been shown to positively influ-
ence sympathetic innervation of BAT, while their deficiency predis-
poses mice to diet-induced obesity [156]. As aforementioned, S100B is
increased in plasma of female patients under clozapine treatment
[114]; however, it should be mentioned that an elevation in circulating
S100B does not necessarily mean a positive effect in the functional
innervation of BAT, since this adipokine can activate innate immune
cells by interaction with receptors for advanced glycation end-products
[157], which might result in defective insulin sensitivity and thermo-
genic function in BAT [158]. Further studies are required to address the
impact of the higher plasma levels of S100B upon SGA treatment.
Nevertheless, other reports describe different effects of SGAs on BAT
gene expression. Treatment of female C57Bl/6 J mice with risperidone
for 3 weeks (4mg/kg/day, intraperitoneal) increases food intake and
body weight, and is associated with reduced locomotor activity in the
first 2 days after the first injection, and without alterations in the core
body temperature at this time period [159]. Yet, at the end of the third
week, the body temperature of animals receiving risperidone increased,
and this was associated with lower locomotor activity during the dark
phase. Also, expression of UCP-1 in BAT and UCP-3 in gastrocnemius
was elevated by risperidone, whereas the mRNA encoding orexin A was
decreased in the hypothalamus. These results suggest that risperidone-
induced weight gain in mice is a consequence of increased energy in-
take and reduced activity, whereas the higher body temperature may be
a result of diet-induced thermogenesis and elevated UCP-1 and UCP-3
together with reduced hypothalamic orexin A expression [159]. By
contrast, using male Sprague-Dawley rats treated with olanzapine
(1mg/kg/day) in food for 6weeks, Minet-Ringuet and co-workers re-
ported no alterations in mitochondrial thermogenesis in the BAT of
olanzapine-treated animals. Even in the presence of guanosine dipho-
sphate, which inhibits UCP-1, the respiratory rates at different mem-
brane potentials showed no alterations in proton conductance after the
treatment [160]. Considering the apparent contradictory results in
some of these studies, we cannot discard that these outcomes might be
related, at least in part, to the different binding affinities, doses and/or
administration routes of the SGAs tested.
Co-therapies have also been tested to counteract the side effects of
SGAs in BAT function. Specifically, and since the antagonism of these
drugs to histaminergic receptors was identified as a main contributor to
body weight alterations, the H1 receptor agonist and H3 receptor an-
tagonist betahistine was tested in female Sprague-Dawley rats as a co-
therapy together with olanzapine (3mg/kg/day in cookie dough) for
3 weeks after 23 days of olanzapine treatment and then followed by 19
days of washout [161]. Betahistine co-therapy reduced (45%) the body
weight gain induced by olanzapine and counteracted the olanzapine-
induced increases in H1 receptor protein levels and AMPKα phosphor-
ylation in the hypothalamus, as well as the decrease in UCP-1 and PGC-
1α in BAT. Importantly, this work led to the hypothesis that olanzapine-
induced AMPK activation in the hypothalamus mediates weight im-
balances by diminishing BAT thermogenesis through the hypothalamic
H1 receptor-AMPK pathway [161]. These results align with the effects
of specific genetic activation of hypothalamic AMPK in the ven-
tromedial nucleus of the hypothalamus, which counteracts the central
effect of the thyroid hormone triiodothyronine in BAT activation [162].
Another tested co-therapy is the nonselective β-adrenergic-blocker
propranolol, which can mitigate risperidone (0.75mg/kg/day, oral
gavage for 4 weeks)-induced alterations in BAT in C57BL/6 J females by
increasing UCP-1 and PGC-1α levels [163].
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3.2. The impact of second-generation antipsychotics on BAT cytokine
expression
Beyond the impact of SGAs on BAT adipogenesis, lipogenesis and
function, the aforementioned study by Oh et al. [129] showed that
differentiation of murine brown pre-adipocytes in the presence of clo-
zapine also modulates the expression of adipokines by reducing resistin,
leptin and adiponectin. The same outcome was observed for resistin and
leptin levels in quetiapine-treated cells, whereas ziprasidone was un-
able to affect adipokine expression. Again, the effect of these SGAs in
leptin expression reflects their ability to induce weight gain [129]. Of
interest, leptin synthesis and secretion is modulated by insulin [164]
and it has been reported that SGAs treatment interferes with insulin
signaling [165], although it has not yet been reported in BAT. In such
case, the impact of SGAs on the insulin response in BAT might po-
tentiate the reduction of leptin levels [129]. Additionally, the role of
UCP-1 in augmenting the anorexigenic effect of leptin should also be
considered [166], suggesting that in synergy with the direct suppres-
sion of leptin expression, clozapine also reduces leptin actions through
inhibition of UCP-1 expression [129]. Independently of these studies,
some reports suggest that clozapine increases the serum levels of this
adipokine in patients with schizophrenia [167]. Of interest, the work of
Zhang et al. discussed above [130] in rats treated with olanzapine
showed increased infiltration of macrophages in BAT, which was ac-
companied by up-regulation of the inflammatory cytokines TNF-α, IL-
1β and IL-6, suggesting that olanzapine can trigger peripheral in-
flammation. Moreover, these inflammatory cytokines are also up-
regulated in the hypothalamus [96], an effect possibly related to the
undermining of thermogenesis, as previously described outwith the
context of SGAs treatment [168].
4. Effect of second generation antipsychotics on beige adipose
tissue
Beige adipose tissue is found within the white depots, most notably
in subcutaneous depots. Like BAT, beige adipocytes are characterized
by high amounts of mitochondria and by their ability to dissipate en-
ergy by thermogenesis due to the considerable levels of UCP-1 [16].
Kristof et al. showed that ex vivo treatment of human ASCs isolated from
20 to 65-year-old healthy volunteers (BMI<29.9) with clozapine
(100 ng/ml) during differentiation resulted in a 10-fold increase of their
expression levels of UCP-1, pointing to a beiging/browning process of
these precursors [169]. The up-regulation of UCP-1 mRNA levels was
associated with increased expression of other browning marker genes,
including TBX1. Indeed, the addition of clozapine to differentiating
ASCs resulted in a 1.5-fold increase in the number of beige cells. This
pattern of browning-related gene expression was up-regulated even
when the cells were treated only in the last 2 or 4 days of the differ-
entiation process, suggesting that clozapine can promote a white-to-
beige shift in adipocyte cell fate in the latter stages of differentiation.
However, in spite of the increase in browning, the cells were unable to
activate basal thermogenesis unless they were stimulated with β-adre-
nergic agonists. Independently of this, clozapine added for 12 h to
terminally-differentiated adipocytes from ASCs failed to alter their ex-
pression profile of beiging-related genes. This suggests that there is a
critical stage of the differentiation process at which clozapine commits
mesenchymal adipocyte progenitors to beige adipocytes. In addition,
the lipid droplets found in the differentiated-clozapine treated cells
were smaller and presented a multiocular distribution, which was as-
sociated with increased levels of mitochondrial DNA, but with dimin-
ished sensitivity to cAMP stimulation [169]. In this regard, defective
cAMP signaling has been found in the brain of humans [170] and mice
[171] under SGAs treatment. By contrast, and as mentioned above,
treatment of white adipocytes with olanzapine during differentiation
augments lipid accumulation. Moreover, differentiation of human ASCs
in the presence of olanzapine, ziprasidone, risperidone, quetiapine,
haloperidol (all used at 50 ng/ml) or aripiprazole (100 ng/ml) failed to
alter UCP-1 expression [169]. Of interest, elevations of peripheral ser-
otonin levels in obese mice have been described to inhibit beiging, as
well as the sensitivity of both beige and brown cells to thermogenic
stimulus, in a cell autonomous manner [172,173]. Also, increased levels
of peripheral serotonin [174] and polymorphisms in the gene encoding
tryptophan hydroxylase 1, which catalyzes the rate-limiting step of
serotonin production outside the CNS, are associated with obesity
[175]. The importance of serotonin signaling was demonstrated by
Kristof and co-workers, who co-treated adipocytes [55] with exogenous
serotonin and clozapine during differentiation, and found a partial re-
duction of browning caused by the lowered expression of brown-related
genes. Of interest, the serotonergic receptor HTR2A was found up-
regulated in clozapine-treated adipocytes [169], and it has recently
been described that HTR2A activation results in Gq-mediated signaling
capable of abolishing browning in mice and humans [176]. In fact, Gq
protein expression negatively correlates with UCP-1 levels in the WAT
in mice. Given this, and considering that clozapine antagonizes several
serotonergic receptors with specific high affinity for HTR2A [177], the
alteration in Gq signaling induced by serotonin can, at least in part,
explain the unexpected results of Kristof and co-workers. Of interest,
clozapine is a well-known agonist of H4 receptors [178,179], which are
highly expressed in adipocytes. In a recent study where these receptors
were knocked-down in subcutaneous WAT, cold-induced browning and
lipolysis were abolished. By contrast, when 4-methylhistamine, a se-
lective H4 receptor agonist, was adjacently injected in subcutaneous
WAT, browning was increased through activation of p38/MAPK and
ERK1/2/MAPK signaling pathways, together with an acceleration in
metabolic rate and tolerance to hypothermia [180]. Considering these
results, the increased browning in ASCs treated with clozapine de-
scribed by Kristof et al. could be a consequence, at least in part, of H4
receptor activation. Nevertheless, more studies are required to under-
stand the precise impact of SGAs in beige adipocytes and the browning
process. In this sense, the study by Kristof et al. [169] is an excellent
start. Moreover, it highlights specific signaling pathways that might
affect the differentiation of the adipocytes by clozapine, with special
importance to serotonergic signaling, pointing to a possible co-ther-
apeutic approach to ameliorate the adverse effects of these drugs in the
pool of beige adipocytes.
5. Concluding remarks
The study of adipose tissue depots as both metabolically-active tis-
sues and endocrine organs that orchestrate peripheral insulin action,
inflammation and energy expenditure is a relatively new field. Much
effort is being directed to understand the relevance of adipose tissues as
triggers of metabolic dysfunctions and/or possible therapeutic targets
for metabolic pathologies including those associated with SGAs treat-
ment. In this review, we have attempted to illustrate the modulation of
adipocyte fate and their metabolic and endocrine functions by SGAs,
both in cell-based systems and in pre-clinical and clinical studies. These
drugs can modulate white adipocyte differentiation, resulting in in-
creased lipid accumulation and adiposity that is related to the clinical
manifestations of patients under SGAs therapy in an apparent gender-
dependent manner. Also, SGAs exacerbate the chronic low-grade in-
flammatory processes of WAT by augmenting the expression and se-
cretion of pro-inflammatory cytokines and the recruitment of immune
cells, which is associated with altered secretory patterns of adipokines
correlating with obesity, insulin resistance and hyperphagia. These
processes are clearly main contributors to the evident metabolic dys-
functions under SGAs therapy. In addition, SGAs treatment impacts
brown adipogenesis and BAT homeostasis through their ability to
modulate the thermogenic differentiation program by controlling the
expression of UCP-1, also in a gender-dependent manner. Similarly,
browning of white adipocytes is altered by SGAs, particularly clozapine.
Only one study so far has examined this particular adipose depot, but it
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could be a crucial factor in the secondary side-effects during SGAs
treatments. Another important but less studied theme is how the CNS-
adipose axis is affected by SGAs. The central outputs of this axis are
major coordinators of peripheral adipose tissue function and home-
ostasis by supplying neurotransmitters and, in this regard, alterations in
the neuronal circuits that control energy expenditure or food intake
boost the peripheral disturbances in synergy with specific cell autono-
mous effects of the SGAs. Finally, and not covered in this work, meta-
bolic deficits in patients under SGAs treatment might be due to the
defective cross-talk between fat and liver/skeletal muscle, which are
key tissues for de novo lipogenesis or glucose uptake, respectively.
In conclusion, despite the great strides made in our understanding of
the metabolic consequences of the treatment with SGAs, further in-
vestigations are required to fully address the impact of SGAs in the
different adipose tissue depots of the organism and the interactome
between them either by inflammatory molecules, adipokines and/or
other activator or inhibitory compounds, as well as the connections
between the CNS and fat.
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